Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury

Basit Öğe Kaydı
dc.contributor.authorLevendoglu, F
dc.contributor.authorOgun, CO
dc.contributor.authorOzerbil, O
dc.contributor.authorOgun, TC
dc.contributor.authorUgurlu, H
dc.date.accessioned2020-03-26T16:55:17Z
dc.date.available2020-03-26T16:55:17Z
dc.date.issued2004
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractStudy Design. Prospective, randomized, double blind, placebo-controlled, crossover clinical trial. Objectives. To determine the efficacy of gabapentin in the treatment of neuropathic pain related to spinal cord injury. Summary of Background Data. Neuropathic pain is initiated or caused by a primary lesion or dysfunction in the nervous system. Neuropathic pain associated with spinal cord injury is quite refractory, and current treatments are not effective. Gabapentin, an anticonvulsant, has become the first choice in the treatment of neuropathic pain. The place of gabapentin in the treatment of spinal cord injury-related neuropathic pain was questioned in only a few recent reports; however, they are retrospectively designed, nonstandardized, and uncontrolled studies, or involve a very small series of patients using less than optimum doses. Methods. A total of 18-week study period included a 4-week medication/ placebo titration period. This was followed by a 4-week stable dosing period when the patients continued to receive maximum tolerated doses, a 2-week washout period, then a crossover of 4 weeks of medication/ placebo titration, and another 4 weeks of stable dosing period. Twenty paraplegic patients (female/male: 7/13) with complete spinal cord injury at the thoracic and lumbar level, aged between 20 and 65 years, with neuropathic pain for more than 6 months were recruited for the study. Results. All patients completed the study. Gabapentin reduced the intensity as well as the frequency of pain, relieved all neuropathic pain descriptors except the itchy, sensitive, dull, and cold types, and improved the quality of life ( P < 0.05). Conclusions. Gabapentin can be added to the list of first-line medications for the treatment of chronic neuropathic pain in spinal cord injury patients. It is a promising new agent and offers advantages over currently available treatments.en_US
dc.identifier.doi10.1097/01.BRS.0000112068.16108.3Aen_US
dc.identifier.endpage751en_US
dc.identifier.issn0362-2436en_US
dc.identifier.issn1528-1159en_US
dc.identifier.issue7en_US
dc.identifier.pmid15087796en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage743en_US
dc.identifier.urihttps://dx.doi.org/10.1097/01.BRS.0000112068.16108.3A
dc.identifier.urihttps://hdl.handle.net/20.500.12395/19075
dc.identifier.volume29en_US
dc.identifier.wosWOS:000220693600006en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLIPPINCOTT WILLIAMS & WILKINSen_US
dc.relation.ispartofSPINEen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectneuropathic painen_US
dc.subjectspinal cord injuryen_US
dc.subjectgabapentinen_US
dc.titleGabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injuryen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
gabapentin_is_a_first_line_drug_for_the_treatment.7.pdf
Boyut:
460.83 KB
Biçim:
Adobe Portable Document Format
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu